LDE-225 Diphosphate

LDE-225 Diphosphate 구조식 이미지
카스 번호:
1218778-77-8
상품명:
LDE-225 Diphosphate
동의어(영문):
LDE 225 phosphate;NVP-LDE225;LDE225;Sonidegib phosphate;LDE 225 Diphosphate;LDE-225 Diphosphate;LDE225 (Diphosphate);Erismodegib phosphate;Sonidegib diphosphate;NVP-LDE 225 Diphosphate;ErisModegib Diphosphate
CBNumber:
CB42666648
분자식:
C26H32F3N3O11P2
포뮬러 무게:
681.4885116
MOL 파일:
1218778-77-8.mol

LDE-225 Diphosphate 속성

저장 조건
Store at -20°C
용해도
≥27.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
물리적 상태
백색 고체.

안전

LDE-225 Diphosphate C화학적 특성, 용도, 생산

개요

Sonidegib phosphate (XXIX), an orally bioavailable, small molecule smoothened (SMO) receptor antagonist developed by Novartis, was approved in 2015 in Switzerland, the U.S., and the EU for the treatment of adult patients with advanced or locally advanced basal cell carcinoma (BCC). BCC is the most frequently diagnosed skin cancer, constituting 80% of all nonmelanoma skin cancers. While most BCCs can be treated through surgery or radiation therapy, some patients (<10%) have more advanced tumors for which surgery may be contraindicated or impractical; treatment options for these patients are limited. SMO, a G-protein coupled receptor-like protein (GPCR), is a key regulator in the hedgehog (Hh) pathway, which is activated in a number of tumors including BCC. In a multicenter clinical trial for sonidegib, an objective response rate of 43% was observed for patients with locally advanced BCC (dosing at 200 mg once daily), with sustained clinically meaningful responses based on an 18-month analysis. Sonidegib joins vismodegib as marketable treatments of BCC. Vismodegib, which was approved in 2012 as a first-in-class SMO receptor antagonist, represented the first Hedgehog signaling pathway targeting agent to gain FDA approval.

용도

NVP-LDE225 Diphosphate Salt is a potent, selective, and orally bioavailable Smoothened (Hedgehog Signaling Pathway) antagonist.

정의

ChEBI: A phosphate salt obtained by reaction sonidegib with two equivalent of phosphoric acid. Used for treatment of locally advanced basal cell carcinoma.

LDE-225 Diphosphate 준비 용품 및 원자재

원자재

준비 용품


LDE-225 Diphosphate 공급 업체

글로벌( 72)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 967 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
InvivoChem
+1-708-310-1919 +1-13798911105
sales@invivochem.cn United States 6393 58
LEAP CHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 24738 58
ShenZhen Trendseen Biological Technology Co.,Ltd.
13417589054
trendseenbio@gmail.com China 11681 58
Nanjing Fred Technology Co., Ltd
+86-25-84696168 +86-15380713688
Austin@fredbio.com China 2449 58
Amadis Chemical Company Limited
571-89925085
sales@amadischem.com China 131981 58
Beijing Jingzi Pharmaceutical Technology Co., Ltd. 15011485209
17241816@qq.com China 81 58
Shanghai Boyle Chemical Co., Ltd.
sales@boylechem.com China 2923 55

Copyright 2019 © ChemicalBook. All rights reserved